|
시장보고서
상품코드
2131517
종양성 골연화증 시장 규모, 점유율, 성장 분석 : 진단별, 치료별, 최종사용자별, 지역별 - 산업 예측(2026-2033년)Tumour-Induced Osteomalacia Market Size, Share, and Growth Analysis, By Diagnosis (Laboratory Testing, Imaging), By Treatment (Surgical Treatment, Drug Therapy), By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 종양성 골연화증 시장 규모는 2024년에 1억 7,400만 달러로 평가되며, 2025년 1억 9,575만 달러에서 2033년까지 5억 226만 달러로 확대될 전망이며, 예측 기간(2026-2033년) 동안 CAGR 12.5%로 성장할 것으로 전망됩니다.
세계 종양성 골연화증(TIO) 시장은 진단 키트 및 외과적 치료법의 혁신과 상용화, 그리고 브로스맙(Brosumab)과 같은 섬유아세포 성장 인자-23(FGF-23) 항체라는 신규 약물군의 등장이 특징입니다. TIO는 희귀질환인 반면, 뼈의 석회화에 심각한 영향을 미치기 때문에 표적 치료법에 대한 꾸준한 수요가 발생하고 있습니다. 당초 인지도 부족과 침습적인 치료법의 존재로 인해 시장은 과제에 직면해 있었으나, 최근의 기술 발전과 희귀질환 치료제에 대한 규제적 지원이 성장을 뒷받침하고 있습니다. AI를 활용한 영상 진단 기술의 도입으로 진단 정확도가 향상되고 종양을 조기에 식별할 수 있게 됨에 따라 조기 치료의 길이 열리고 있습니다. 이러한 기술의 통합은 수술 성과를 향상시킬 뿐만 아니라 치료법 채택 확대도 촉진하고 있으며, TIO 분야의 생명공학 혁신에 대한 막대한 투자를 유치하고 있습니다.
세계 종양성 골연화증 시장의 성장요인
세계 종양성 골연화증 시장은 이 질환의 미묘한 징후에 대한 임상의들의 인식이 높아짐에 따라 성장을 거듭하고 있습니다. 이러한 인식 제고로 인해 환자의 조기 의뢰와 보다 상세한 진단 평가가 이루어지고 있습니다. 그 결과, 첨단 영상 진단 기술의 도입이 확대되고 있으며, 내분비 전문의, 종양 전문의, 방사선과 전문의 등 전문가 간의 협력이 강화되고 있습니다. 이러한 진보로 인해 환자 치료 과정이 효율화되고, 진단 지연이 최소화되며, 치료 솔루션의 이용 가능성이 높아지고 있습니다. 또한, 교육 활동과 최신 임상 지침은 조기 발견의 중요성을 강조하는 데 있어 매우 중요한 역할을 하고 있으며, 이에 따라 시장 내 관련 의료 제품 및 서비스에 대한 수요가 지속적으로 증가하고 있습니다.
세계 종양성 골연화증 시장의 제약요인
세계 종양성 골연화증 시장은 정확한 진단에 필수적인 전문적인 영상 진단 기술에 대한 접근성이 고르지 않은 점에 크게 제약을 받고 있으며, 특히 자원이 부족한 지역에서 이 현상이 두드러집니다. 이러한 격차로 인해 근본적인 병변의 확인이 지연되고, 환자의 불편함이 장기화되며, 필요한 치료 개입이 미뤄지는 결과를 초래하고 있습니다. 적절한 영상 진단 능력을 갖추지 못한 의료 기관은 종종 효과가 낮은 대체 수단을 사용할 수밖에 없으며, 그 결과 진단 결과가 모호해져 임상적 불확실성을 증가시킬 가능성이 있습니다. 그 결과, 시장에서 첨단 진단 도구의 도입은 제한적이며, 이는 궁극적으로 전 세계 의료 시스템 내에서 관련 치료법의 광범위한 수용과 시행을 저해하고 있습니다.
세계 종양성 골연화증 시장의 동향
세계 종양성 골연화증 시장은 진단 및 치료 전략에 정밀 유전체학을 통합하는 것을 원동력으로 삼아 현저한 발전을 이루고 있습니다. 차세대 염기서열 분석 및 표적 유전자 패널로의 전환을 통해 임상의는 근본적인 중간엽성 종양을 정확하게 식별할 수 있게 되었으며, 이는 조기 진단과 맞춤형 치료 개입을 촉진하고 있습니다. 이러한 유전체학에 대한 중점은 종양학, 내분비학, 분자병리학 간의 학제간 협력을 촉진하여 환자 치료를 개선하는 효율적인 다학제 진료 체계의 확립으로 이어지고 있습니다. 또한, 유전적 요인에 대한 이해가 깊어짐에 따라 제약사들은 동반진단법 개발에 주력하고 있으며, 그 결과 개별적으로 최적화된 치료법이 급증하여 전 세계 다양한 의료 현장에서 시장 동향을 주도하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 종양성 골연화증 시장 규모 : 진단별
세계의 종양성 골연화증 시장 규모 : 치료별
세계의 종양성 골연화증 시장 규모 : 최종사용자별
세계의 종양성 골연화증 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.10.01Global Tumour-Induced Osteomalacia Market size was valued at USD 174.0 Million in 2024 and is poised to grow from USD 195.75 Million in 2025 to USD 502.26 Million by 2033, growing at a CAGR of 12.5% during the forecast period (2026-2033).
The global market for tumour-induced osteomalacia (TIO) is characterized by the innovation and commercialization of diagnostic kits, surgical options, and the novel class of fibroblast growth factor-23 (FGF-23) antibodies such as burosumab. The rarity of TIO, combined with its serious effects on bone mineralization, creates a robust demand for targeted therapies. Though the market initially faced challenges due to limited awareness and invasive treatment options, recent advancements and regulatory support for orphan drugs have fostered growth. The utilization of AI-driven imaging technologies enhances diagnostic accuracy and facilitates timely tumor localization, promoting earlier treatment pathways. This integration not only improves surgical outcomes but also drives an increase in treatment adoption, attracting significant investment in biotech innovations within the TIO space.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tumour-Induced Osteomalacia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Tumour-Induced Osteomalacia Market Segments Analysis
Global tumour-induced osteomalacia market is segmented by diagnosis, treatment, end user and region. Based on diagnosis, the market is segmented into Laboratory Testing, Imaging and Tumor Localization Techniques. Based on treatment, the market is segmented into Surgical Treatment, Drug Therapy and Supportive Care. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Tumour-Induced Osteomalacia Market
The Global Tumour-Induced Osteomalacia market is experiencing growth driven by improved clinician awareness regarding the subtle indicators of the condition. This increased recognition leads to earlier patient referrals and more extensive diagnostic evaluations. Consequently, there is a rising adoption of advanced imaging technologies and enhanced collaboration among specialists such as endocrinologists, oncologists, and radiologists. These advancements streamline patient care pathways, minimizing diagnostic delays and promoting the availability of therapeutic solutions. Moreover, educational initiatives and updated clinical guidelines play a crucial role in emphasizing the significance of early detection, thus fueling ongoing demand for related medical products and services within the market.
Restraints in the Global Tumour-Induced Osteomalacia Market
The global Tumour-Induced Osteomalacia market is significantly hindered by inconsistent access to specialized imaging technologies essential for accurate diagnosis, particularly in under-resourced areas. This disparity results in delays in identifying the underlying lesions, prolonging patient discomfort and postponing necessary treatment interventions. Healthcare facilities without the appropriate imaging capabilities are often forced to use less effective alternatives, which may yield ambiguous results and exacerbate clinical uncertainty. As a result, there is a limited adoption of advanced diagnostic tools in the market, ultimately impeding the broader acceptance and implementation of related treatment options within the healthcare system worldwide.
Market Trends of the Global Tumour-Induced Osteomalacia Market
The Global Tumour-Induced Osteomalacia market is experiencing a significant evolution driven by the integration of precision genomics in diagnostics and treatment strategies. The shift towards next-generation sequencing and targeted gene panels empowers clinicians to accurately identify underlying mesenchymal tumors, facilitating early diagnosis and personalized therapeutic interventions. This genomic emphasis fosters interdisciplinary collaboration among oncology, endocrinology, and molecular pathology, leading to the establishment of streamlined, multidisciplinary clinics that enhance patient care. Furthermore, as the understanding of genetic factors increases, pharmaceutical companies are focusing on developing companion diagnostics, resulting in a surge of tailored therapies that are propelling market growth across diverse global healthcare landscapes.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Tumour-Induced Osteomalacia Market Size by Diagnosis & CAGR (2026-2033)
- Market Overview
- Laboratory Testing
- Imaging
- Tumor Localization Techniques
Global Tumour-Induced Osteomalacia Market Size by Treatment & CAGR (2026-2033)
- Market Overview
- Surgical Treatment
- Drug Therapy
- FGF23 Inhibitors
- Phosphate & Vitamin D Therapy
- Supportive Care
Global Tumour-Induced Osteomalacia Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Academic & Research Institutes
Global Tumour-Induced Osteomalacia Market Size & CAGR (2026-2033)
- North America (Diagnosis, Treatment, End User)
- US
- Canada
- Europe (Diagnosis, Treatment, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Diagnosis, Treatment, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Diagnosis, Treatment, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Diagnosis, Treatment, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Kyowa Kirin Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ultragenyx Pharmaceutical Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Inozyme Pharma, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BridgeBio Pharma, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ascendis Pharma A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioMarin Pharmaceutical Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alexion Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
